IntelGenx Technologies (IGX) Stock Price, News & Analysis

Company Overview

IntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine. The company's products under development comprise INT0004/2006, an antidepressant; INT0046/2018 for adult use; INT0007/2006 for the treatment of erectile dysfunction; INT0010/2006 for the treatment of neuropathic pain and nausea in cancer patients; INT0027/2011 to treat opioid addition; INT0036/2013 for schizophrenia; and INT0043/2015 to treat Alzheimer's disease; and INT0048/2020 for animal health. It is also developing INT0039/2013, INT0040/2014, INT0052/2020, and INT0053/2020. The company has licensing, development, and supply agreement with Tilray, Inc. and Gensco Pharma; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was founded in 2003 and is headquartered in Montreal, Canada.

Key Stats

• Today's Range: C$0.58 to C$0.60
• 50-Day Range: C$0.58 to C$0.58
• 52-Week Range: C$0.17 to C$0.85
• Volume: 11,848 shs
• Average Volume: 56,279 shs
• Market Capitalization: C$87.32 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

IGX Stock Analysis - Frequently Asked Questions

How have IGX shares performed this year?

IntelGenx Technologies' stock was trading at C$0.58 at the beginning of 2024. Since then, IGX shares have increased by 0.0% and is now trading at C$0.58.
View the best growth stocks for 2024 here.

How do I buy shares of IntelGenx Technologies?

Shares of IGX stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What other stocks do shareholders of IntelGenx Technologies own?

Based on aggregate information from My MarketBeat watchlists, some other companies that IntelGenx Technologies investors own include IntelGenx Technologies (IGXT), F-star Therapeutics (FSTX), Trican Well Service (TCW), Aurora Cannabis (ACB), New Age Brands (NF), AutoZone (AZO) and Bonterra Energy (BNE).

Industry, Sector and Symbol

• Stock Exchange: CVE
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Chemicals
• Current Symbol: CVE:IGX
• CUSIP: N/A
• CIK: N/A
• Web: www.intelgenx.com
• Phone: 514-331-7440
• Fax: N/A
• Employees: 2,050
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 164.62
• Current Ratio: 2.77
• Quick Ratio: 2.69

Sales & Book Value

• Annual Sales: C$1.75 million
• Price / Sales: 49.95
• Cash Flow: C$0.08 per share
• Price / Cash Flow: 7.16
• Book Value: C$0.05 per share
• Price / Book: 12.89

Miscellaneous

• Outstanding Shares: 150,546,000
• Free Float: N/A
• Market Cap: C$87.32 million
• Optionable: Not Optionable
• Beta: N/A